Greg Siller

Summary

Country: Australia

Publications

  1. ncbi PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study
    Greg Siller
    Siller Medical Pty Ltd and Dermatology Group, The University of Queensland, Queensland, Australia
    Australas J Dermatol 50:16-22. 2009
  2. ncbi PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial
    Greg Siller
    Siller Medical Pty Ltd, Brisbane, Queensland, Australia
    Australas J Dermatol 51:99-105. 2010
  3. ncbi An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma
    Jason K Wu
    Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
    Australas J Dermatol 47:46-8. 2006
  4. ncbi Psoriasis induced by topical imiquimod
    Jason K Wu
    Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
    Australas J Dermatol 45:47-50. 2004
  5. ncbi Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study
    Yin Vun
    Siller Medical, Brisbane, Queensland, Australia
    Australas J Dermatol 47:169-71. 2006
  6. ncbi The effect of skin examination surveys on the incidence of basal cell carcinoma in a Queensland community sample: a 10-year longitudinal study
    Patricia Casarolli Valery
    Queensland Institute of Medical Research, Australian Center for International and Tropical Health and Nutrition, University of Queensland, Queensland, Australia
    J Investig Dermatol Symp Proc 9:148-51. 2004
  7. ncbi Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream
    Jason K Wu
    Department of Dermatology, Princess Alexandra Hospital, Queensland, Australia
    Australas J Dermatol 44:123-5. 2003
  8. ncbi Pigmented spindle cell naevus of Reed: a controversial diagnostic entity in Australia
    Scott A Webber
    Department of Dermatology, Princess Alexandra Hospital, Queensland, Australia
    Australas J Dermatol 52:104-8. 2011

Collaborators

Detail Information

Publications8

  1. ncbi PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study
    Greg Siller
    Siller Medical Pty Ltd and Dermatology Group, The University of Queensland, Queensland, Australia
    Australas J Dermatol 50:16-22. 2009
    ..05% had clinical clearance of at least four of five treated lesions (P = 0.0185 vs vehicle gel). Ingenol mebutate gel is being developed as a short-course topical therapy for actinic keratosis and non-melanoma skin cancer...
  2. ncbi PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial
    Greg Siller
    Siller Medical Pty Ltd, Brisbane, Queensland, Australia
    Australas J Dermatol 51:99-105. 2010
    ..To evaluate the safety of two applications of PEP005 (ingenol mebutate) gel in superficial basal cell carcinoma. Efficacy was a secondary end-point...
  3. ncbi An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma
    Jason K Wu
    Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
    Australas J Dermatol 47:46-8. 2006
    ..Curettage followed by imiquimod 5% cream is effective for the treatment of primary nodular basal cell carcinoma on the trunk and limbs, and most patients are pleased with the cosmetic outcome...
  4. ncbi Psoriasis induced by topical imiquimod
    Jason K Wu
    Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
    Australas J Dermatol 45:47-50. 2004
    ..Nine-and-a-half weeks after completing treatment the patient developed disseminated small psoriatic lesions. Other recognized triggers of psoriasis were not identified. The psoriasis resolved slowly with conventional treatment...
  5. ncbi Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study
    Yin Vun
    Siller Medical, Brisbane, Queensland, Australia
    Australas J Dermatol 47:169-71. 2006
    ..We found that 5% imiquimod cream is an effective treatment option for superficial and nodular basal cell carcinomas, giving a clearance rate of 89.5% at an average of 39 months of follow up...
  6. ncbi The effect of skin examination surveys on the incidence of basal cell carcinoma in a Queensland community sample: a 10-year longitudinal study
    Patricia Casarolli Valery
    Queensland Institute of Medical Research, Australian Center for International and Tropical Health and Nutrition, University of Queensland, Queensland, Australia
    J Investig Dermatol Symp Proc 9:148-51. 2004
    ..We conclude that BCC that might otherwise go unreported are detected during skin examination surveys and thus that such skin cancer screening can influence the apparent burden of skin cancer...
  7. ncbi Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream
    Jason K Wu
    Department of Dermatology, Princess Alexandra Hospital, Queensland, Australia
    Australas J Dermatol 44:123-5. 2003
    ..This tumour showed an unusual histological picture, with normal epidermis overlying residual BCC in the papillary dermis. The Bowen's disease remains clinically clear at 12-months follow up...
  8. ncbi Pigmented spindle cell naevus of Reed: a controversial diagnostic entity in Australia
    Scott A Webber
    Department of Dermatology, Princess Alexandra Hospital, Queensland, Australia
    Australas J Dermatol 52:104-8. 2011
    ..A further aim of our study was to determine the approach of dermatology trainees in this country to the management of this type of lesion...